ANGIOGENESIS MODULATORS - An Exclusive Market Insight Report Update

Angiogenesis plays a prominent role in development and expansion of cancer cells. The new blood vessel formed supplies the cancer tumor with the required oxygen and nutrients.

Hyderabad, India (prHWY.com) May 7, 2012 - April 18, 2012- RI Technologies' (http://www.researchimpact.com/) report on Angiogenesis Modulators studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, cardiology, ophthalmology, and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. Compilation of Worldwide Patents and Research related to Angiogenesis is also provided. The study includes estimations and predictions for the total global angiogenesis therapeutic products market. Estimations and predictions are also graphically illustrated by geographic regions encompassing the US, Europe, Asia-Pacific and Rest of World.

Angiogenesis plays a prominent role in development and expansion of cancer cells. The new blood vessel formed supplies the cancer tumor with the required oxygen and nutrients, thus facilitating its expansion to the neighboring regions. Both natural and synthetic angiogenesis inhibitors are under development for different therapeutic areas such as Oncology, Central Nervous System, Dermatology, and Ophthalmology. Use of Cartilage (Shark) derived Inhibitor is been used widely as a secondary treatment of non-responsive solid cancer tumors. Development of 'proteosome' is expected to attract more patients towards anti-angiogenesis therapy for the treatment of various tumor types.


About RI Technologies

RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector with exclusive focus on product segments, global and regional market analysis, technology trends, industry outlook, competitor profiles, corporate directory and patents information. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The dedicated team works 24/7 to deliver unique reports that are of immense value to investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools. The company's reports provide strategic information tools to the manufacturers, retailers, distributors, and suppliers that will help them to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. The strategic market information tables, graphically represented, will aid companies' research needs and help in forecasting, and gearing up to the future. Emphasis is on factual insights and forecasts with maximum global coverage. The company strives to provide market insight reports that empower customers with enlightening critical business information.

###

Tag Words: angiogenesis modulators

Categories: Research

Press Release Contact
Customer Support: contactus@researchimpact.com. Call us at INDIA: +91 9676994272 / UK: 076-24-057837 for your biotechnology and healthcare market research report requirements. We provide 24/7 online.

Link To This Press Release:

URL HTML Code